Payment overview · 2025
General Payments
$13.66
1 reported records · 1 companies
Healthcare provider profile · identity verified
Kumar Akashdeep, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · STURGEON BAY, WI · NPI 1720210008
Verified facts
What the public records show
CMS Open Payments records show Kumar Akashdeep, M.D. received $13.66 in general payments during 2025 across 1 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.66 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $13.66 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABILIFY Normalized: abilify |
Drug | E.R. Squibb & Sons, L.L.C. | $13.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
114 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 717 | 201 |
| Amlodipine Besylate | Amlodipine Besylate | 408 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 365 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 307 | 77 |
| Losartan Potassium | Losartan Potassium | 295 | 84 |
| Omeprazole | Omeprazole | 267 | 81 |
| Lisinopril | Lisinopril | 264 | 70 |
| Metformin Hcl | Metformin Hcl | 256 | 67 |
| Gabapentin | Gabapentin | 225 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 170 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 157 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 150 | 43 |
| Jardiance | Empagliflozin | 147 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 39 |
| Simvastatin | Simvastatin | 117 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 30 |
| Allopurinol | Allopurinol | 114 | 34 |
| Eliquis | Apixaban | 114 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 112 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 49 |
| Ozempic | Semaglutide | 111 | 19 |
| Tramadol Hcl | Tramadol Hcl | 105 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 41 |
| Furosemide | Furosemide | 97 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 45 |
| Potassium Chloride | Potassium Chloride | 92 | 27 |
| Metformin Hcl Er | Metformin Hcl | 91 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 26 |
| Januvia | Sitagliptin Phosphate | 82 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 75 | 29 |
| Sertraline Hcl | Sertraline Hcl | 75 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 74 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 69 | 11 |
| Alprazolam | Alprazolam | 66 | 14 |
| Ezetimibe | Ezetimibe | 66 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 19 |
| Famotidine | Famotidine | 62 | 12 |
| Atenolol | Atenolol | 57 | 17 |
| Finasteride | Finasteride | 57 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 15 |
| Glipizide | Glipizide | 56 | 17 |
| Warfarin Sodium | Warfarin Sodium | 56 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 16 |
| Nifedipine Er | Nifedipine | 53 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 52 | 17 |
| Carvedilol | Carvedilol | 51 | 16 |
| Methylprednisolone | Methylprednisolone | 50 | 42 |
| Pregabalin | Pregabalin | 50 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | 25 |
| Buspirone Hcl | Buspirone Hcl | 48 | 12 |
| Mirtazapine | Mirtazapine | 48 | 11 |
| Montelukast Sodium | Montelukast Sodium | 48 | 14 |
| Spironolactone | Spironolactone | 47 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 46 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 44 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Glimepiride | Glimepiride | 43 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 24 |
| Chlorthalidone | Chlorthalidone | 42 | 11 |
| Lorazepam | Lorazepam | 42 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | 13 |
| Celecoxib | Celecoxib | 40 | 18 |
| Bumetanide | Bumetanide | 39 | suppressed |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 38 | suppressed |
| Meloxicam | Meloxicam | 36 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 11 |
| Propranolol Hcl | Propranolol Hcl | 35 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Prednisone | Prednisone | 34 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | 11 |
| Baclofen | Baclofen | 32 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 20 |
| Clonazepam | Clonazepam | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | 11 |
| Lovastatin | Lovastatin | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Nystatin | Nystatin | 26 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 24 |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 11 |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 13 |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Amantadine | Amantadine Hcl | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Acarbose | Acarbose | 15 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Nystop | Nystatin | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 11 |
| Fluconazole | Fluconazole | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13.66 · 1 records | E.R. Squibb & Sons, L.L.C. | ABILIFY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error